ClinicalTrials.Veeva

Menu

Pets Enhancing Therapeutics in Intensive Care Units (PET-ICU)

U

University Hospital, Clermont-Ferrand

Status

Not yet enrolling

Conditions

Intensive Care Unit (ICU) Patients
Dog Therapy

Treatments

Other: Pet dog visit

Study type

Interventional

Funder types

Other

Identifiers

NCT07159568
2025-A00615-44 (Other Identifier)
AOI 2024 LALANDE

Details and patient eligibility

About

Intensive Care Units (ICUs) are well known for their therapeutic and environmental aggressiveness. Current recommendations for the management of critically ill patients, including the "ABCDEF bundle," emphasize family engagement and liberal visitation policies for relatives and loved ones, with the aim of improving patient well-being during their ICU stay.

In France, half of all households own a pet. This close relationship between humans and animals explains why animals have long been involved in medical care. The earliest known use of animals in medicine dates back to the 9th century in Belgium, where they were used to assist individuals with mental illness. More recently, companion animal-assisted interventions have attracted growing interest due to their potential diagnostic and/or therapeutic value, as they may enhance the patient experience during hospitalization. The feasibility, safety, and potential benefits of pet visitation policies have mainly been assessed in conventional hospital wards, but remain understudied in the ICU setting. In France, to our knowledge, only three hospitals have allowed pet visits in the ICU, and these occurred outside of any research protocol.

The study primary objective is to assess the feasibility of companion dog visits in three medical-surgical ICUs.

Enrollment

21 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Adult patient aged 18 years or older,
  • Admitted to one of the participating ICUs at Clermont-Ferrand University Hospital (Estaing Adult ICU, Montpied Medical-Surgical ICU, or Montpied Neuro-ICU) with an expected ICU stay of 48 hours or more,
  • Owner of a companion dog, with family members or relatives able to bring the dog to the ICU.

Exclusion criteria

Patient-related exclusion criteria:

  • Refusal by the patient or by their family/relatives to participate,
  • Lack of affiliation with the French national health insurance system (Sécurité Sociale),
  • Patient deprived of liberty or under legal protection (guardianship, curatorship, or judicial safeguard),
  • Pregnant or breastfeeding patient,
  • Agitated patient, defined as a Richmond Agitation-Sedation Scale (RASS) score > 0 (monitored every four hours according to current standard practice),
  • Patient with immunosuppression, defined as: blood neutrophil count < 0.5 G/L, ongoing or recent (within the past month) treatment for solid or hematologic cancer (e.g., chemotherapy, radiotherapy, cell therapy), or receiving immunosuppressive drugs (including organ transplant recipients or corticosteroid therapy for more than two weeks),
  • Patient with known colonization by multidrug-resistant bacteria (as routinely assessed upon ICU admission and weekly thereafter),
  • Patient with one or more open wounds or injuries that cannot be covered with a dressing.

Dog-related exclusion criteria:

  • Dog belonging to category 1 or 2 breeds considered dangerous under current French regulations,
  • Dog that never leaves the home environment,
  • Dog with an incomplete vaccination status,
  • Dog with a known transmissible disease.

Trial design

Primary purpose

Other

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

21 participants in 1 patient group

Pet dog visit
Experimental group
Treatment:
Other: Pet dog visit

Trial contacts and locations

1

Loading...

Central trial contact

Lise Laclautre

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems